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Background: Breast cancer mortality is declining in many Western countries. If mammography screening
contributed to decreases in mortality, then decreases in advanced breast cancer incidence should also be noticeable.
Patients and methods: We assessed incidence trends of advanced breast cancer in areas where mammography
screening is practiced for at least 7 years with 60% minimum participation and where population-based registration of
advanced breast cancer existed. Through a systematic Medline search, we identified relevant published data for
Australia, Italy, Norway, Switzerland, The Netherlands, UK and the USA. Data from cancer registries in Northern
Ireland, Scotland, the USA (Surveillance, Epidemiology and End Results (SEER), and Connecticut), and Tasmania
(Australia) were available for the study. Criterion for advanced cancer was the tumour size, and if not available, spread
to regional/distant sites.
Results: Age-adjusted annual percent changes (APCs) were stable or increasing in ten areas (APCs of 20.5% to
1.7%). In four areas (Firenze, the Netherlands, SEER and Connecticut) there were transient downward trends followed
by increases back to pre-screening rates.
Conclusions: In areas with widespread sustained mammographic screening, trends in advanced breast cancer
incidence do not support a substantial role for screening in the decrease in mortality.
Key words: breast cancer, cancer registry, incidence, screening, stage
introduction
Since 1990, breast cancer mortality in women has fallen in
many countries with populations of mainly European ancestry
[1–3]. This improvement in mortality could be related to
earlier detection of cancer with screening and the efficacy of
treatments. Studies done so far have not been able to assess
with precision how much of the mortality decrease was due to
screening or to adjuvant therapy. For instance, a study that
developed seven independent statistical models found that
the contribution of screening to decreases in breast cancer
mortality in the United States could range from 28%
to 65% [4].
Mammographic screening aims to detect cancer at an
earlier stage that would be less life threatening and easier to
cure than if detected clinically. Diagnosis procedures are not
influenced by subsequent treatments. Hence, a reduction of
advanced cancer incidence should reflect the impact of
screening activities alone, thus providing an estimate of the
contribution of screening to the observed mortality decrease.
Longstanding broad consensus exists for considering
a decrease in advanced breast cancer incidence as the best
early indicator of the impact of screening [5–11]. Following
this logic, in a previous work, we found that when all
randomised trials of mammographic screening were
considered, breast cancer mortality reductions were directly
proportional to the fall in the incidence of advanced breast
cancer [12].
In the United States, nationwide mammographic screening
has been introduced in 1983 and screening coverage of women
‡40 years reached 50% in 1990 and 71% in 1997 [13]. In
a recent report, using data from the Surveillance,
Epidemiology and End Results (SEER) cancer registries,
Esserman et al. [14] concluded that breast screening may
increase the burden of low-risk cancers without significantly
reducing the incidence of more aggressively growing tumours.
In view of these unexpected conclusions, we performed
a systematic review of published data on incidence trends of
advanced breast cancer incidence in areas where
mammographic screening was in operation for ‡7 years and
where participation to screening was high. We could also
make use of relevant data made available by several
population-based cancer registries established in areas with
high mammography screening coverage.
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patients and methods
criteria for data or study selection
Data or studies were selected if they reported time trend of advanced
invasive breast cancer incidence in the general population, outside the
context of randomised trials or cohort studies. Further inclusion criteria
were details on cancer size or on stage; incidence reported for at least 7
years after commencement of breast cancer screening and screening
attendance in target group of ‡60% per biennium (triennium in the UK)
during at least the last 3–4 years of observation.
We excluded studies that reported size or stage as a percentage of total
number of cancer cases, as this type of metric varies with the number of
smaller tumours detected [14]. We also excluded studies that obtained
results via application of mathematical models to cancer registry data.
search for published data on size- or stage-specific
breast cancer incidence
The literature review was performed using Medline from January 1990 to
June 2009. Algorithms incorporating keywords: ‘breast cancer’, ‘size’,
‘stage’, and ‘trends’ were used. We searched for keywords in the title and
abstract, without language restrictions.
In addition, we performed a manual search of references cited in the
selected articles, in related articles according to Medline and in
International Agency for Research on Cancer library resources, e.g. the
articles used for the Handbook on Breast Cancer Screening [7]. We also
performed searches for publicly available reports from bodies in charge of
screening programmes.
Data from peer-reviewed articles was supplemented with data from
several population-based cancer registries whose data were published in
Cancer in Five Continents volumes VIII and IX (www-dep.iarc.fr).
definition of advanced breast cancer
Breast cancer invasive component size was used as an indicator for
advanced disease. The size for distinguishing early and advanced cancers
was 20 mm as this threshold also distinguishes tumour classes T1 and T2 or
above in both the tumour–node–metastasis (TNM) and American Joint
Committee on Cancer manuals [15, 16].
If size was not available, data were examined by stage at diagnosis.
Stage I cancers were considered as early, and stages II–IV as advanced
since stage I breast cancers are equal or <20 mm and are without lymph
node involvement or distant metastases. Several registries reported
cancer as localised (cancer confined to the breast, including nipple and
areola), regional (cancer invading surrounding tissues or
involving axillary or internal mammary lymph nodes) or distant (cancer
involving infraclavicular, supraclavicular, cervical or other distant
lymph nodes or systemic metastases) according to the Surveillance,
Epidemiology and End Results (SEER) classification method [17]. We
used the term ‘non-local’ cancer when we talked of both regional and
distant cancers.
data extraction and analysis
This study concentrates on invasive breast cancer. When data were not
reported in tables, we extracted incidence rates by digitising figures using
the two-dimensional coordinate tool of the Acrobat software (Adobe
Acrobat, version 7.1).
Statistical analyses were performed on age groups targeted for screening.
However, incidence rates reported in publications sometimes covered larger
age groups. For the nine oldest SEER areas and Connecticut, we took
women aged 40–69 years, as screening in the United States is most frequent
in this age range [18]. Studies often used different reference populations for
age adjustment of incidence rates. Two studies on women aged 50–69 years
in Firenze (Italy) [19] and in Norway [20] did not report age adjustment,
but because of the narrow age range studied, this is unlikely to have
changed overall trends.
Log-linear regressions were fitted to estimate changes in age-adjusted
incidence over time, from which we derived annual percent changes (APC)
and 95% confidence intervals (95% CI) [21]. When incidence data were
reported for years preceding screening, APC calculations included the 3
years before the presumed start year, but not earlier data. Rates for New
South Wales were reported for 4 years only, 1986, 1988, 1992, and 1995
[22]. Therefore, before APC calculation, rates of a given year were
interpolated to directly preceding and following years. In years where rates
were still missing, the average of two closest years was computed. In Geneva
(Switzerland), because rates by 5-year age blocks were reported, we took
APCs computed by authors [23]. A trend was labelled significant if the 95%
CI did not include 0.
results
study selection
We retrieved 590 articles published in peer-reviewed journals.
Application of the selection criteria resulted in the retention of
35 studies. Twenty-seven were excluded for the following
reasons:
1 They were earlier reports of SEER data USA [24–31], of the
Connecticut Tumour Registry [32, 33], of Firenze (Italy)
cancer registry [34, 35], and of pilot screening project in
Norway [36];
2 Areas where screening was operational for <7 years or where
reported data mainly concerned the prevalent screening
round [37, 38];
3 Studies not based on population-based cancer registries or
conducted in selected sub-groups (e.g. membership of
a health insurance plan) or without appropriate
denominator [39–49].
4 Studies with erratic variations in stage over time most
probably reflecting changes in practice (e.g. sentinel node
biopsy) [50].
Data of eight studies published in peer-reviewed journals
displayed in Table 1 were used [8,19–23, 51, 58, 59], related to
areas in Australia, Italy, The Netherlands, Norway, Switzerland,
and the United States. For The Netherlands, we also retrieved
a report and a congress abstract issued by the Dutch National
Evaluation Team for Breast Cancer Screening that reported
incidence rates of advanced cancer for more recent years [53,
60]. Data collected by the Tasmania Cancer Registry [52], the
Northern Ireland Cancer Registry [54], the Scottish Cancer
Registry [55], the nine oldest SEER areas [56], the National
Cancer Institute’s Historical Connecticut Tumour Registry
(part of the nine oldest SEER registries) [57] satisfied the
eligibility criteria and were available for this study.
Screening coverage (proportion of the woman population for
which screening is available) and participation (women
regularly attending screening) have gradually increased in all
areas, included in this study. In all areas, the percentage of
eligible women participating in mammography screening was
high, ranging from 60% in Firenze (Italy) to 88% in Rhode
Island (USA). Details on screening activities in selected can be
found in the additional material, available at Annals of Oncology
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Table 1. Temporal trends in incidence of early and of advanced BC
Country and area Data source
[reference]
Cancer registry Cancer categories
for advanced BC
Study period Population source Studied age
groups
% Women with
missing data
Female
population in
studied age groups
Incidence of
APC (%) 95% CI
Australia
New South
Wales
Kricker et al. [22] New South Wales
Central Cancer
registry
‡20 mm 1986, 1989, 1992,
1995
New South Wales
Central Cancer
registry
50–69 7 550 000 1.6 0.7–2.5
‡30 mm 21.5 22.4 to20.5
Victoria Harmer et al. [51] Victoria Cancer
Registry
>15 mm 1988–1996 Victoria Cancer
Registry
‡25 23 1 519 824 1.0 20.1 to 2.0
Tasmania Tasmania Cancer
Registry [52]
Tasmania Cancer
Registry
‡20 mm 1997–2007 Tasmania Cancer
Registry
All ages NA 250 000 1.5 20.3 to 3.4
‡50 mm 20.2 23.7 to 3.5
Italy
City of Firenze Pacci et al. [19] Tuscany Cancer
Registry
‡20 mm 1990–1999 Resident female
population
invited to
screening until
1996a
50–69 NA 54.495 21.6 24.4 to 1.3
The Netherlands
All the country Frachebound
et al.;
NTBEC [8, 53]
The Netherlands
Cancer
Registry
>20 mm 1989–2000 The Netherlands
Cancer
Registry
50–69 <5 1 591 200 22.0 22.7 to 21.2
>20 mm and
metastasis in
node or in
distant organs
21.6 22.3 to 20.9
Northern Ireland
All the country Northern Ireland
Cancer Registry
[54]
Northern Ireland
Cancer
Registry
‡20 mm 1993–2003 Northern Ireland
Cancer
Register
50–64 14 131 479 0.6 20.4 to 1.6
‡30 mm 1.6 0.1–3.2
Norway
Four countiesb Hofvind et al. [20] Cancer Register of
Norway
Non-localc 1993–2003 NordCan
databased
50–69 24 181 400 1.7 b1.2–2.2
Scotland
All the country Scottish Cancer
Registry [55]
Scottish Cancer
Registry
‡20 mm 1993–2007 Scottish Cancer
Registry
50–64 9 490 613 0.4 20.6 to 1.6
‡30 mm 0.5 20.7 to 1.8
Switzerland
Geneva Verkooijen et al.
[23]
Geneva Cancer
Registry
Non-localc 1985–1999 Verkooijen
et al. [23]
All ages 1 200 000 0.12g P = NS
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Table 1. (Continued)
Country and area Data source
[reference]
Cancer registry Cancer categories
for advanced BC
Study period Population source Studied age
groups
% Women with
missing data
Female
population in
studied age groups
Incidence of
APC (%) 95% CI
United States of America
Nine oldest
SEER areas
9 oldest SEER
registries [56]
9 oldest SEER
registriese
Non-localc 1980–2007 SEERf 40–69 4 6 134 000 20.4 20.6 to 0.1
Distant 0.1 20.2 to 0.3
Connecticut Connecticut
Tumour
Registry (part
of nine oldest
SEER areas)
[57]
Connecticut
Tumour
Registry (part
of nine oldest
SEER areas)
Non-localc 1980–2006 Connecticut
Tumour
Registry
40–69 4 621 000 20.5 20.8 to 0.2
Distant 21.0 21.6 to 20.5
New Mexico Escobedo et al.
[58]
New Mexico
Tumour
Registry
Non-localc 1980–1997 SEER (f) All ages NA 901 033 20.3 20.7 to 0.1
Rhode Island Coburn et al. [59] Non-localc 1995–2001h Coburn et al. [59] ‡40 NAi 250 00 20.1 NA
APC, annual percents change in %; BC, breast cancer; 95% CI, 95% confidence interval; NA, not reported or data not available for making calculations; NS, statistically non significant.
aData from Paci et al 2002 [35] for female population until 1996, and estimation until from 1996 to 1999 obtained using projection based on linear regression.
bCounties of Akerhus, Hordaland, Oslo, Rogaland.
cLocal, regional, or distant SEER stage (Shambough et al. [17]): regional and distant extension were grouped as non-local.
dEngholm et al. [61].
eConnecticut, Hawaai, Iowa, New Mexico, Utah, Atlanta, Detroit, San Francisco-Oakland, Seattle-Puget Sound.
fhttp://seer.cancer.gov/popdata/download.html.
gIncidence data reported by 5-year blocks; APC as reported by Verkooijen et al. [23].
hIncidence data for 1995-97 and 1999-2002 (see Figure 1).
iMissing data on stage was reported as ‘‘low’’ after 1993, without other precision.
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online. For the SEER and Connecticut Tumor Registry, before
1998, size was missing for 20%–42% of invasive cancers and
thus, we used the local/regional/distant classification for which
there were 3.6% unstaged cancers per year on average.
advanced breast cancer incidence
Temporal trends in size-specific breast cancer in the 11 main
studies are reported as APC in Table 1. Figures 1–3 display
temporal trends in advanced breast cancer incidence.
The differences in incidence rates between areas were partly due
to differences in the age groups considered and to the use of
different reference populations for standardisation of rates.
Such differences do not affect time trends.
In Firenze (Figure 1), the incidence of advanced cancers was
reported for a single year (1990) before the screening
programme started. The rate decreased abruptly in 1991 and
then stabilised until 1998, and in 1999, it came back to the 1990
level. The APC of21.6% is essentially due to the high 1990 rate
at the beginning.
In The Netherlands, the National Evaluation Team for Breast
Cancer Screening published size-specific incidence from 1989
until 1997 [8]. Incidences until 2000 were displayed in the 11th
Evaluation Report [53]. In 2008, incidence rates by TNM stage
until 2003 were reported during the International Union Against
Cancer (UICC) World Cancer Congress in Geneva, Switzerland
[60]. The incidence of cancers over 20 mm in women 50–69 first
decreased by 12.2% from 1989 to 1997 with the lowest rate
observed in 1998 (Figure 1). However, rates increased again in
1999 and 2000. The report made during the 2008 UICC World
Cancer Congress in Geneva (Switzerland) concluded that ‘the
initially observed decrease of advanced breast cancers after the
implementation of mammography screening did not continue
after 1997, but, was followed by an increase to the initial level’
[60]. Of note, in this report, ‘advanced’ equals cancers >20 mm
in size with positive lymph nodes and/or distant metastases (M1)
which represented 60% of all cancers >20 mm.
In Northern Ireland and in Scotland, trends in cancer ‡20
mm remained stable (Figure 1).
No change in incidence of advanced cancers occurred in the
four Norwegian counties in the years following implementation
of the pilot screening programmes in 1996.
In Geneva, Switzerland, trends in incidence rates of localised
and non-localised (SEER definition) were reported separately
for ductal and lobular invasive carcinoma. The latter type of
breast cancer is more difficult to detect by mammography and
we retained only data for ductal carcinoma.
No change in the incidence of advanced ductal cancers was
evident in Geneva.
In the nine oldest SEER registries (USA), during a 16-year
period, the incidence trends of non-local cancers were erratic
with periods of decrease alternating with periods of increase
(Figure 2). In 2001, rates had returned to levels before screening
started. After 2000, the incidence of advanced cancers
decreased, but similar decreases were noticeable for early cancer
(<20 mm size of local cancers, data not displayed) [62]. The
population in Connecticut represent 14% of the population in
the nine oldest SEER areas. From 1975 to 2006, the incidence of
non-local cancer fluctuated like the nine oldest SEER areas. In
1995, the Breast and Cervical Cancer Early Detection Program
was launched. The incidence of advanced cancer peaked again
in 2000 when participation to screening had reached 84%. Alike
the nine oldest SEER areas, the incidence of advanced cancers
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Figure 1. Age-adjusted incidence rates of advanced breast cancer in Northern Ireland, Scotland, Firenze (Italy), The Netherlands, Geneva (Switzerland), and
Norway. The interrupted vertical line indicates the year of screening start. Criterion for advanced cancer is a tumour size > or ‡20 mm (dots) or non-local
cancer (squares). Rates were age adjusted using the World standard population (for Northern Ireland and Scotland) and the European standard population
(for The Netherlands and Geneva). No information on age-adjustment was provided for the Norway pilot project and for Firenze (Italy).
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decreased after 2000, but larger decreases were noticeable for
early cancer (<20 mm size of local cancers, data not displayed).
In New Mexico, the incidence of advanced cancers increased
slightly from 32.3 per 100 000 women of all ages in 1979–80 to
36.9 in 1983–84. It remained the same in 1985–86 and slightly
decreased to 34.2 in 1987–88. After 1987–88, the incidence
remained stable until 1997 and was not affected by the Breast
and Cervical Cancer Early Detection Program launched in
1991.
In Rhode Island, the annual incidence of stages II–IV breast
cancers in women 40 years of age and more was unchanged at
132.0 per 100 000 for the period 1995–97 and 131.3 for the
period 1999–2001 (incidence rates for 1998 were not
reported).
In Victoria, New South Wales, and Tasmania, trends in
advanced cancer remained constant over time (Figure 3).
Incidence of large cancers or of cancer that already had
disseminated in distant organ at diagnosis was available in
some areas (Table 1). Cancer ‡30 mm size represented 50% and
46% of all cancer ‡20 mm in Northern Ireland and in Scotland,
respectively. Upward trends of cancer ‡30 mm were noticeable.
In the nine oldest SEER registries (USA), distant cancers
represented15% of all non-local cancers. Their incidence
remained stable in thenineoldSEERregistries,while inConnecticut
significant downward trends were noticeable with APC of21.0%
from 1980 to 2006. However, the decrease in the incidence of
advanced breast cancer observed until 1995 started in years
preceding screening start and well before participation to screening
was substantial (APC 1975–2006:21.1%; 95% CI21.6 to20.6).
In New South Wales, while there was a significant decrease
in the incidence of cancers ‡30 mm (APC =21.5; 95% CI22.4
to 20.5), there was a concomitant strong increase in the
incidence of cancers 20–29 mm (APC = 4.1%; 95% CI 3.5% to
4.7%). In Tasmania, the incidence of cancers >49 mm remained
stable over the 11-year period of observation.
Missing data on size or stage were variable, from 1% in Geneva
(Switzerland) to 24% inNorway.No association between amounts
of missing and time trends were noticed (data not shown).
discussion
In areas included in this study, breast cancer mortality fell
dramatically after 1990 with APCs ranging from 21.7% to
22.5% [1–3]. Often, mortality decreases started before
screening started or was offered to the majority of women. In
examining trends of breast cancer by size or by stage, we
expected to observe decreases in the incidence rate of advanced
breast cancer. In contrast, this study found that in general,
incidence rates of advanced breast cancer did not change much
despite 7–15 years of good participation in mammographic
screening. There were variations in some areas, with transient
downward trends. These, however, were followed by increases
back to pre-screening rates. For instance, in The Netherlands,
trends in the falling incidence of advanced cancer for the first 7
years of screening were compatible with the results of most
trials. However, incidence rates in 2003 were close to initial
values in 1989 just before the launch of the national breast
screening programme. Likewise, the rates of advanced breast
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Figure 2. Age-adjusted incidence rates of advanced breast cancer in the United States. The interrupted vertical line indicates the year of screening start
(not displayed in Rhode Island where it started in 1983). The doted line is the first year of the Breast and Cervical Cancer Early Detection Program. Criterion
for advanced cancer is a tumour size >20 mm (dots) or non-local cancer (squares), or (for Rhode Island) stages II–IV (squares). Rates were age adjusted
using the 2000 US standard population but for New Mexico where the 1970 US standard population was used.
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cancer in the USA in 2000 were nearly back to levels before
screening started. The fall of rates in the USA after 2001 was
linked to massive drops in the use of hormone replacement
treatment (HRT) after publication of the Women’s Health
Initiative trial, and falls of rates have affected breast cancer of all
stages and of all sizes [31, 62]. Similar rate decreases of early
and advanced breast cancer after massive cessation of HRT use
by postmenopausal women have been observed in other
countries [63, 64].
Comparison of breast screening activities showed that the
numbers of large screen-detected cancers >20 mm were very
similar in the USA and the UK in spite of considerable differences
in the way screening is implemented [65, 66]. These elements
indicate that the lower than expected decrease in advanced cancer
incidence seems not attributable to age at screening, to screening
frequency or to the way screening is implemented.
Randomised trials of breast cancer screening and their
reviews concluded that mammographic screening of women
aged 50–69 years decreases breast cancer mortality by 20% to
25% [8, 67]. In a previous work, we showed that in these trials,
breast cancer mortality reductions were directly proportional to
the fall in the incidence of advanced breast cancer [12]. Results
of this study do not concur with expectations from
mammography randomised trials despite the fact that women
living in areas included in this study were at least as compliant
to screening and had more screening rounds than women had
in the intervention groups of most randomised trials. For
instance, in the Swedish Two-County trial, the cumulative
incidence of advanced breast cancer steadily decreased by 4.4%
per year in women allocated to mammography compared with
the control group [5, 6]. Two to four screening rounds at 24–33
month-interval lead to a 31% reduction in advanced breast
cancer incidence and 32% in breast cancer mortality [12]. In
contrast, until 2002 (when the massive discontinuation of
hormone replacement treatment took place), no or only little
change occurred in the incidence of advanced breast cancer in
the USA, despite that over >10–15 years, most US women 40–
69 years had three to five times more mammography screenings
than in the Two-County Trial.
Other cancers subject to screening have shown remarkable
decreases in both the incidence of advanced cancer and of
mortality. For instance, in the USA, similarly to breast cancer
mortality, colorectal cancer mortality has decreased by 1.8%
per year from 1990 to 2006 [68]. A substantial contribution of
earlier detection to the reduction of mortality is supported by
steady decreases in the incidence of regional (22.5% per year)
and of distant (21.2% per year) colorectal cancer in the SEER
data [69]. In Iceland, age-adjusted annual mortality rate from
cervical cancer decreased from 5.0 per 100 000 in 1974–78 to
2.1 in 1999–2003 [61]. At the same time, incidence of stages
II–IV cervical cancer decreased by a factor two to three,
depending on age [70].
What are the possible reasons for modest or no reduction in
the incidence of advanced breast cancer?
First, in the absence of screening, would advanced breast
cancer incidence have increased as the incidence of earlier
breast cancer? This is very unlikely since generalisation of
mammographic screening has been itself at the origin of sharp
increases in the incidence of small breast cancers, many of
which are deemed to be of low malignant potential [71]. In The
Netherlands, no increase in proportions of advanced cancers in
women not attending screening was observed [53], and there
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Figure 3. Age-adjusted incidence rates of advanced breast cancer in Victoria and New South Wales (Australia). The interrupted vertical line indicates the
year of screening start. Criterion for advanced cancer is a tumour size >15 mm in Victoria and ‡20 mm in New South Wales and Tasmania. Rates were age
adjusted using the World standard population for Victoria and Tasmania and the 1991 Australia standard population for New South Wales.
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were no time changes in the incidence of advanced breast
cancer in women <50 and >69 years of age in which screening is
rare [8]. In Victoria (Australia), the incidence of advanced
breast cancer in non-attending women was similar to that
observed among screened women [51].
Second, reassurance of women with negative screening could
have led to greater numbers of interval cancer >20 mm. This is
unlikely to be the case. A study in The Netherlands concluded
that this factor played only a minor role in breast cancer
screening [72].
Mammographic screening aims to detect tumours in the
breast, rather than lymph node or distant metastases.
Therefore, size of invasive cancer was preferred to other
indicators of cancer progression. Furthermore, contrary to
axillary node status, cancer size measurement has remained
stable over time [12]. In this respect, some of the fluctuations in
rates of cancers classified as ‘regional or distant’ in the USA
may have been due to changes over time in lymph node status
assessment and improvements in the diagnosis of disseminated
cancer. Changes in lymph node status assessment have also
been invoked for explaining the absence of persistent
downward trend of the advanced breast cancer incidence in The
Netherlands [60, 73]. But the stable incidence in large size
cancer we have observed cannot be explained by changes in
lymph node status assessment.
Our study has several limitations. In Victoria, New Mexico,
and Switzerland, incidence rates were reported for wider age
groups than those targeted by screening. However, 96% of
breast cancers occur after age 39 [68] and any decrease in
advanced breast cancer occurrence due to screening before age
70 is expected to persist after that age. In the USA, screening
after 69 years of age is common and nationwide surveys showed
that in 1997–98, 57% of US women aged ‡70 received screening
within 2 years [18].
We did not find much published data on breast cancer
incidence by cancer size or stage. This was often due to the
absence of a population-based cancer registry or lack of
recording of data on disease advancement by registries. Some
registries reported high levels of missing stage or size data [10].
In many countries, co-existence of centrally organised
screening programmes and non-centrally organised
screening activities (see additional material, available at Annals
of Oncology online) made it difficult to obtain the same quality
statistics related to both types of screening.
In conclusion, there are unexpected differences between the
results of randomised trials and screening with mammography
as applied in general populations which require further
investigation. Cancer registries should as a matter of routine
collect size of breast cancers and the screening status to enable
further monitoring of the impact of mammographic breast
cancer screening.
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